This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Direct costs
No long-term costs were reported, hence discounting was not required. Resource use was collected from patients enrolled in the randomised controlled trial for a number of cost categories. More specifically, drug therapy, luteal support, ultrasound, the pre-admission clinic, fixed theatre costs, fixed anaesthetic costs, theatre time, time on the ward, clinic visits (including tests), patient travel costs, patient expenditure on medicines and counselling, and hospital costs associated with miscarriage. Adverse events were assumed to be equal across both groups. The costs to relatives were excluded. The resource quantities and the unit prices were both reported for hospital costs, as well as the average cost per patient. The treatment costs incurred by the patient were recorded as dollar amounts only. Resource use was measured during 1996 to 1999 and was priced at 1998 prices.
Statistical analysis of costs
The costs were not treated stochastically.
Indirect Costs
Discounting was, again, not appropriate. The study recorded time lost to "work or normal home duties" after treatment. Only a total dollar amount per person and the daily rate for lost income (based on local pay rates) were reported.
Currency
New Zealand dollars (NZ$). Some costs were also reported in US dollars ($) and UK pounds sterling ().
Sensitivity analysis
Sensitivity analysis was applied to the hospital costs for laser treatment and to the drug treatment costs for OI, both independently (one-way sensitivity analysis) and jointly (two-way sensitivity analysis).
Estimated benefits used in the economic analysis
See the 'Effectiveness Results' section.
Cost results
The total per patient costs, including adverse events, were NZ$2,593.23 for LOD and NZ$5,461.29 for OI.
The incremental cost of OI over LOD was also reported in US dollars ($3,645) and UK pounds sterling (2,132).
Synthesis of costs and benefits
Although the authors referred to their study as a cost-minimisation analysis, they did report both the cost per pregnancy and the cost per live birth for LOD and OI.
The cost per pregnancy was $10,938 for LOD and $16,549 for OI.
The cost per live birth was $21,095 for LOD and $28,744 for OI.
The authors expressed concern that the lack of miscarriages in this small sample might have been due to chance (other studies have found similar rates of miscarriage). Consequently, they assumed that the miscarriage rates in the LOD group were the same as those in the OI group and reduced the number of live births from 8 to 4 accordingly.
No incremental costs were reported, nor was there any analysis by sub-group.
Sensitivity analysis took the form of re-calculating all categories of treatment costs at 125% and 150% of their original levels. The effect that these altered values had on the cost per live birth was not reported.
In a two-way sensitivity analysis, the cost-advantage of LOD remained even if the LOD costs were increased by 25% with a simultaneous 25% reduction in OI costs.
Only when the LOD costs were increased by 50%, with the OI costs simultaneously reduced by 50%, did OI achieve a slight cost-advantage.
No formal statistical analysis was reported.
Authors' conclusions
Laparoscopic ovarian diathermy (LOD) is considerably less expensive than ovulation induction (OI). The costadvantage of LOD is likely to increase over time because LOD has been shown to improve the chances of subsequent pregnancies without further intervention. The probability of multiple pregnancies was reported as being a further disadvantage of OI. LOD was also reported to be preferable because of the ease of treatment that it offers women.
CRD COMMENTARY -Selection of comparators
The choice of OI as the comparator to LOD treatment was justified as representing current practice. You are advised to ensure that OI represents a valid comparator in your own setting.
Validity of estimate of measure of effectiveness
The study was based on a randomised controlled trial, which was appropriate for the study hypothesis. There was no evidence that the study sample was representative of the study population, although there was no reason to suppose that they were not. There was also no information on the comparability of the groups before treatment. The number of live births was adjusted on the basis of the assumption that the number of miscarriages was lower than might be expected. This may be misleading to anyone undertaking a meta-analysis of these data. It also appears questionable to base the number of miscarriages on the number of women in the study, rather than on the number of pregnancies, as it is impossible to miscarry unless pregnancy is achieved. The measures of benefit (pregnancies and live births) were taken directly from the effectiveness analysis. The authors acknowledged that the two techniques each carry their own risk of complications. With drug therapy there is a risk that pregnancy might result in multiple births. For laser treatment there is a risk of adhesions and possible long-term effects on ovarian function. These have implications, both for the health of the patient and for the costs.
Validity of estimate of measure of benefit
The measure of benefit was taken directly from the clinical study. Please see the comments under the 'Validity of estimate of measure of effectiveness' field (above).
Validity of estimate of costs
As the authors noted, the restriction of the follow-up period to 6 months and the possible exclusion of longer term consequences might have resulted in some understatement of the costs. The cost estimates were derived from small sample sizes. The reporting of the price year, resource use and unit costs was good.
Other issues
The authors compared their findings with those from a modelling exercise that came to similar conclusions about the cost of the two treatments. Caution was expressed with respect to the small scale of the study and women's preferences over treatment modalities. The authors also pointed out that the context of a publicly funded health care system might not be generalisable to, for example, the US health care system in which hospital costs might be higher.
Implications of the study
The findings implied that LOD should be used in preference to OI.
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